Blood System Drugs

Argatroban is a synthetic anticoagulant and a reversible competitive thrombin inhibitor. It has a strong selective inhibitory effect on thrombin and inhibits platelet aggregation caused by thrombin.

The chemical name of terlipressin is triglycidyl lysine vasopressin. It is a new synthetic long-acting vasopressin preparation. It is a precursor drug with no activity. It is used as a chemical book by aminopeptidase in vivo. After removing three glycyl residues at its N-terminal, it slowly "releases" active lysine vasopressin. Therefore, terlipressin is equivalent to a storage library that can release lysine vasopressin at a stable rate.

Prasugrel is a thienopyridine antiplatelet drug developed by Eli Lilly and first pharmaceutical Co., Ltd., a Japanese pharmaceutical company. It is a precursor drug. It forms active molecules in the liver after metabolism by cytochrome P450, and binds with platelet P2Y12 receptor to exert antiplatelet aggregation activity. Clinical studies have proved that 60 mg dose of clopidogrel has better anticoagulant effect than 300 mg standard dose and 600 mg increased dose of clopidogrel, which can reduce the comprehensive risk of heart attack, stroke and death due to heart disease by 20%, and has fast effect, good curative effect, good drug resistance and bioavailability, and low toxicity. Prasugrel also has stronger performance than clopidogrel in stable angina pectoris and acute coronary syndrome interventional surgery, but the stronger the antiplatelet effect is, the easier it is to cause bleeding. Now the key problem is how to identify the high-risk patients of thrombosis and the high-risk groups of bleeding, so that prasugrel and clopidogrel can be used differently in the two high-risk groups, which can reduce coronary thrombosis and avoid major bleeding.

Clevidipine (INN, trade name Cleviprex) is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. It was approved by the United States Food and Drug Administration on August 1, 2008.

Dabigatran ester is a new synthetic direct thrombin inhibitor. It is the precursor of dabigatran and belongs to non peptide thrombin inhibitor. After oral absorption through gastrointestinal tract, it is transformed into dabigatran with direct anticoagulant activity in vivo. Dabigatran binds to the fibrin specific binding site of thrombin and prevents the cleavage of fibrinogen into fibrin, thus blocking the final step of coagulation waterfall network and thrombosis. Dabigatran can dissociate from fibrin thrombin conjugate and play a reversible anticoagulant effect